Mehran Taherian

Dr. Mehran Taherian


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MTMehran Taherian
Mehran Taherian
MKMatthew H. G. Katz
Matthew H. G. Katz
LPLaura Prakash
Laura Prakash
DWDongguang Wei
Dongguang Wei
YTYi Tat Tong
Yi Tat Tong
HWHuamin Wang
Huamin Wang
Adequate sampling is essential to an accurate pathologic evaluation of pancreatectomy specimens resected for pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant therapy (NAT). However, limited data are available for the association between the sampling and survival in these patients. We examined the association of the entire submission of the tumor (ESOT) and the entire submission of the pancreas (ESOP) with disease-free survival (DFS) and overall survival (OS), as well as their correlations with clinicopathologic features, for 627 patients with PDAC who received NAT and pancreaticoduodenectomy. We demonstrated that both ESOT and ESOP were associated with lower ypT, less frequent perineural invasion, and better tumor response (p < 0.05). ESOP was also associated with a smaller tumor size (p < 0.001), more lymph nodes (p < 0.001), a lower ypN stage (p < 0.001), better differentiation (p = 0.02), and less frequent lymphovascular invasion (p = 0.009). However, since ESOP and ESOT were primarily conducted for cases with no grossly identifiable tumor or minimal residual carcinoma in initial sections, potential bias cannot be excluded. Both ESOT and ESOP were associated with less frequent recurrence/metastasis and better DFS and OS (p < 0.05) in the overall study population. ESOP was associated with better DFS and better OS in patients with ypT0/ypT1 or ypN0 tumors and better OS in patients with complete or near-complete response (p < 0.05). ESOT was associated with better OS in patients with ypT0/ypT1 or ypN0 tumors (p < 0.05). Both ESOT and ESOP were independent prognostic factors for OS according to multivariate survival analyses. Therefore, accurate pathologic evaluation using ESOP and ESOT is associated with the prognosis in PDAC patients with complete or near-complete pathologic response and ypT0/ypT1 tumor after NAT.

28 October 2026 in ACG Case Reports Journal
Verified
Journal Article
Open access
SHSean Hormozian
Sean Hormozian
YGYasmin Gore
Yasmin Gore
TKTherence Kotafoya
Therence Kotafoya
AZAndrew Zhang
Andrew Zhang
MTMehran Taherian
Mehran Taherian
ZSZhigang Song
Zhigang Song
Insulinomas are characteristically small pancreatic neuroendocrine tumors, though giant variants have been reported. We describe a 63-year-old woman who presented with refractory hypoglycemia attributable to an exceptionally large 12 cm pancreatic mass that failed to respond to medical treatment. She was quickly taken for surgical resection, after which hypoglycemia quickly resolved. Histopathologic examination demonstrated a well-differentiated pT3N0 neuroendocrine tumor demonstrating negative staining for insulin and pancreatic and duodenal homeobox 1, with positive staining for insulinoma-associated protein 1, alpha-thalassemia/mental retardation X-linked, and alpha-1-antitrypsin. Repeat imaging showed no tumor recurrence. This case illustrates an uncommon presentation and highlights key immunostains in delineating different insulinoma phenotypes.